Drax Biomass Wins Natural-Medicine Patent of the Month for May 2026

The month of May 2026 brings an exciting milestone for the natural-medicine industry, as Drax Biomass, Inc. has officially been awarded the Patent of the Month for their groundbreaking invention, “Biomass processing” (US Patent No. 12590260). This remarkable patent fundamentally revolutionizes how botanical and herbal raw materials are prepared, offering a unique method that forms compressed pellets while eliminating active size-reduction after the drying stage. In highly sensitive natural medicine manufacturing, this means superior preservation of delicate phytochemicals, increased extraction yields, and a significant improvement in the consistency of medicinal botanicals.

What makes this invention truly innovative is its introduction of a multi-stage sizing and screening process before drying, ensuring that materials are optimally sized while retaining natural moisture. Natural-medicine operations often require processing large volumes of raw botanicals without degrading their heat-sensitive or mechanically fragile active compounds. By halting aggressive size reduction after the biomass is dried and seamlessly compressing the pure material into pellets, the system allows manufacturers to focus on high-potency extraction. The result is a massive boost to both product quality and supply-chain stability, effectively addressing long-standing hurdles in botanical processing and earning it the prestigious top spot in the natural-medicine sector for May 2026.

Eligibility for USA R&D Tax Credits

For companies in the USA adopting or iterating upon this biomass processing technology, the practical applications could readily qualify for the Research and Development (R&D) Tax Credit. To be eligible, a business must pass the IRS’s four-part test: the activities must be technological in nature, involve the elimination of technical uncertainty, utilize a process of experimentation, and aim to create a new or improved product or process. A natural-medicine company that tests this novel pelletizing method to improve specific herbal extraction yields, formulates new botanical therapies derived from these stable pellets, or engineers custom manufacturing equipment to integrate this sizing and drying workflow into their existing facility would be actively resolving technical uncertainties. The expenses associated with engineering these new processes, conducting laboratory testing on botanical extracts for potency, and running trial production batches can be claimed as qualified research expenditures, substantially offsetting the financial risks of implementing this cutting-edge processing technology.